Results 181 to 190 of about 244,483 (261)

Drug Utilization Review Board Annual Report 2010-2011

, 2011
New Jersey. Drug Utilization Annual Review Board
core  

The equity gap in precision dosing: a cross-sectional analysis of hospital-wide antimicrobial therapeutic drug monitoring implementation. [PDF]

Front Public Health
Yang B, Zheng B, Wang J, Jiang H, Yang W, Xu H, Han B, Xin C, Zhang M, Tu Y.   +9 more
europepmc   +1 more source

Development of human monoclonal antibodies against TARM1 by yeast display

FEBS Open Bio, EarlyView.
Human monoclonal antibodies against TARM1 are generated by yeast display‐guided selection. These antibodies bind to soluble and cell‐surface forms of TARM1. Also, these antibodies exhibit agonistic activity in the NFAT‐GFP reporter assay, indicating that TARM1 signaling can be functionally modulated by antibodies and suggesting TARM1 as a potential ...
Rikio Yabe, Mayumi Saeki, Masaaki Hashiguchi, Sayaka Ono, Kazuhisa Aoki, Hidetaka Tanno   +5 more
wiley   +1 more source

Drug Utilization Review Board Annual Report 2004-2005

, 2005
New Jersey. Drug Utilization Annual Review Board
core  

"Smart" harm reduction vending machines to improve public health: Evaluating the utilization. [PDF]

J Subst Use Addict Treat
Zhang A, Murphy J, Griffin PM, Goodman-Hinnershitz M, Pinto CN, Ballard SM, Grigson PS, Kawasaki SS, Tuan WJ, Zgierska AE.   +9 more
europepmc   +1 more source

Establishing an assay to evaluate d‐amino acid oxidase enzyme kinetics and inhibition using WST‐8 redox dye

FEBS Open Bio, EarlyView.
This study investigated a novel WST‐8‐based assay for evaluating d‐Amino acid oxidase (DAO) inhibitors. We confirmed its effectiveness using known inhibitors and found that uremic toxins possess relatively weak inhibitory activity compared to existing drugs.
Kahoko Miyake, Yuki Enoki, Yuka Nakazawa, Kazuaki Taguchi, Kazuaki Matsumoto   +4 more
wiley   +1 more source

2014-2015

, 2015
New Jersey. Drug Utilization Annual Review Board
core  

Comparative Cost Evaluation of Managed Entry Agreement Techniques Using Real-World Data from High-Cost Anticancer Drugs in Thailand. [PDF]

J Mark Access Health Policy
Owat P, Sooksriwong C, Ratanabunjerdkul H, Phodha T.   +3 more
europepmc   +1 more source

Matrix metalloproteinase‐9 regulates cell adhesion and membrane protrusive activity of ovarian cancer cells

FEBS Open Bio, EarlyView.
Matrix metalloproteinase‐9 (MMP9) drives ovarian cancer progression. Using MMP9‐null cells (M9‐KO) created from ovarian cancer cells, we found MMP9 loss did not block Epidermal Growth Factor (EGF)‐driven E‐cadherin dissolution or EMT but delayed and reduced EGF‐driven membrane protrusions. Transient MMP9 re‐expression drove membrane protrusion.
Claire Strauel, Sam Bennett, Natalie Ehlinger, Nelson Cook, Katelyn Marvin, Caleb L. Lines, Sam Reyes, Brooke Kirby, Shawn M. Ellerbroek   +8 more
wiley   +1 more source

2015-2016

, 2016
New Jersey. Drug Utilization Annual Review Board
core